Sunday, October 4, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 25, 2026

Jury Orders $3 Million in Punitive Damages Against Meta and YouTube in Landmark Social Media Addiction Trial

View original at finance.yahoo.com
Jury Orders $3 Million in Punitive Damages Against Meta and YouTube in Landmark Social Media Addiction Trial Meta ordered to pay $2.1 million, YouTube $900,000; combined with earlier $3 million compensatory award, total damages reach $6 million LOS ANGELES, March 25, 2026--(BUSINESS WIRE)--A Los Angeles County Superior…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • These companies made deliberate choices that prioritized engagement and profit over the well-being of young people using their products

    60% confidence
  • She began using YouTube at age 6 and Instagram at age 9, and the platforms' deliberately addictive design features caused her to develop anxiety, depression, body dysmorphia and suicidal thoughts

    60% confidence
  • As of 2015, Meta estimated more than 4 million users under the age of 13 were on Instagram, representing approximately 30% of all 10- to 12-year-olds in the United States

    60% confidence
  • Social media companies have profited from targeting children while concealing the addictive and dangerous design features built into their platforms

    60% confidence
  • This verdict sends a clear message to an entire industry that the era of operating without consequence is over

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com